相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Effectiveness of antipsychotic maintenance therapy with quetiapine in comparison with risperidone and olanzapine in routine schizophrenia treatment: results of a prospective observational trial
Reinhold Kilian et al.
EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE (2012)
Assessment of Treatment Algorithms Including Amantadine, Metformin, and Zonisamide for the Prevention of Weight Gain With Olanzapine: A Randomized Controlled Open-Label Study
Vicki Poole Hoffmann et al.
JOURNAL OF CLINICAL PSYCHIATRY (2012)
Rapid improvement of tardive dyskinesia with tetrabenazine, clonazepam and clozapine combined: a naturalistic long-term follow-up study
Itzhak Kimiagar et al.
JOURNAL OF NEUROLOGY (2012)
Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis
Stefan Leucht et al.
LANCET (2012)
Metabolic and cardiovascular adverse effects associated with antipsychotic drugs
Marc De Hert et al.
NATURE REVIEWS ENDOCRINOLOGY (2012)
Antipsychotic treatment for schizophrenia in the maintenance phase: A systematic review of the guidelines and algorithms
Hiroyoshi Takeuchi et al.
SCHIZOPHRENIA RESEARCH (2012)
When can patients with potentially life-threatening adverse effects be rechallenged with clozapine? A systematic review of the published literature
Peter Manu et al.
SCHIZOPHRENIA RESEARCH (2012)
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 1: Update 2012 on the acute treatment of schizophrenia and the management of treatment resistance
Alkomiet Hasan et al.
WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY (2012)
A Randomized Trial Examining the Effectiveness of Switching From Olanzapine, Quetiapine, or Risperidone to Aripiprazole to Reduce Metabolic Risk: Comparison of Antipsychotics for Metabolic Problems (CAMP)
T. Scott Stroup et al.
AMERICAN JOURNAL OF PSYCHIATRY (2011)
Tetrabenazine for the Treatment of Tardive Dyskinesia
Jonathan G. Leung et al.
ANNALS OF PHARMACOTHERAPY (2011)
Dose-associated changes in safety and efficacy parameters observed in a 24-week maintenance trial of olanzapine long-acting injection in patients with schizophrenia
Angela L. Hill et al.
BMC PSYCHIATRY (2011)
Metformin for olanzapine-induced weight gain: a systematic review and meta-analysis
Samir Kumar Praharaj et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Antipsychotics and hyperprolactinaemia: mechanisms, consequences and management
Richard I. G. Holt et al.
CLINICAL ENDOCRINOLOGY (2011)
Assessing QT Interval Prolongation and its Associated Risks with Antipsychotics
Jimmi Nielsen et al.
CNS DRUGS (2011)
Second-generation antipsychotics and constipation: A review of the literature
M. De Hert et al.
EUROPEAN PSYCHIATRY (2011)
Dose correspondence between olanzapine long-acting injection and oral olanzapine: recommendations for switching
Holland C. Detke et al.
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2011)
Evidence-based pharmacotherapy of schizophrenia
Stefan Leucht et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2011)
Orlistat in Clozapine- or Olanzapine-Treated Patients With Overweight or Obesity: A 16-Week Open-Label Extension Phase and Both Phases of a Randomized Controlled Trial
Evgueni Tchoukhine et al.
JOURNAL OF CLINICAL PSYCHIATRY (2011)
Relapse Prevention in First-Episode Schizophrenia-Maintenance vs Intermittent Drug Treatment With Prodrome-Based Early Intervention: Results of a Randomized Controlled Trial Within the German Research Network on Schizophrenia
Wolfgang Gaebel et al.
JOURNAL OF CLINICAL PSYCHIATRY (2011)
Treatment Outcomes of Patients With Tardive Dyskinesia and Chronic Schizophrenia
Stanley N. Caroff et al.
JOURNAL OF CLINICAL PSYCHIATRY (2011)
Mid-Term and Long-Term Efficacy and Effectiveness of Antipsychotic Medications for Schizophrenia: A Data-Driven, Personalized Clinical Approach
Ira D. Glick et al.
JOURNAL OF CLINICAL PSYCHIATRY (2011)
An International Consensus Study of Neuroleptic Malignant Syndrome Diagnostic Criteria Using the Delphi Method
Ronald J. Gurrera et al.
JOURNAL OF CLINICAL PSYCHIATRY (2011)
Topiramate augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study
M. R. A. Muscatello et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2011)
A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia
S. Gopal et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2011)
Deep Brain Stimulation: Current and Future Clinical Applications
Mark K. Lyons
MAYO CLINIC PROCEEDINGS (2011)
Long-Acting Risperidone and Oral Antipsychotics in Unstable Schizophrenia
Robert A. Rosenheck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia
Gahan Pandina et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2011)
A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia
Huafang Li et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2011)
Effects of modafinil on weight, glucose and lipid metabolism in clozapine-treated patients with schizophrenia
David C. Henderson et al.
SCHIZOPHRENIA RESEARCH (2011)
Effects of acute paliperidone palmitate treatment in subjects with schizophrenia recently treated with oral risperidone
Jennifer Kern Sliwa et al.
SCHIZOPHRENIA RESEARCH (2011)
Galantamine augmentation of long-acting injectable risperidone for cognitive impairments in chronic schizophrenia
Jean-Pierre Lindenmayer et al.
SCHIZOPHRENIA RESEARCH (2011)
Oral versus depot antipsychotic drugs for schizophrenia A critical systematic review and meta-analysis of randomised long-term trials
Claudia Leucht et al.
SCHIZOPHRENIA RESEARCH (2011)
Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care
Marc De Hert et al.
WORLD PSYCHIATRY (2011)
Onset of efficacy with acute long-acting injectable paliperidone palmitate treatment in markedly to severely ill patients with schizophrenia: post hoc analysis of a randomized, double-blind clinical trial
Larry Alphs et al.
ANNALS OF GENERAL PSYCHIATRY (2011)
Risperidone Maintenance Treatment in Schizophrenia: A Randomized, Controlled Trial
Chuan-Yue Wang et al.
AMERICAN JOURNAL OF PSYCHIATRY (2010)
Olanzapine Long-Acting Injection: A 24-Week, Randomized, Double-Blind Trial of Maintenance Treatment in Patients With Schizophrenia
John M. Kane et al.
AMERICAN JOURNAL OF PSYCHIATRY (2010)
Research article Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases
Holland C. Detke et al.
BMC PSYCHIATRY (2010)
Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, II: investigations of mechanism
David P. McDonnell et al.
BMC PSYCHIATRY (2010)
Trazodone for the Treatment of Neuroleptic-Induced Acute Akathisia: A Placebo-Controlled, Double-Blind, Crossover Study
Rafael Stryjer et al.
CLINICAL NEUROPHARMACOLOGY (2010)
Practical guidance for dosing and switching paliperidone palmitate treatment in patients with schizophrenia
S. Gopal et al.
CURRENT MEDICAL RESEARCH AND OPINION (2010)
Suicide attempts in a prospective cohort of patients with schizophrenia treated with sertindole or risperidone
M. A. Crocq et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2010)
Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study
Srihari Gopal et al.
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2010)
Paliperidone palmitate - review of the efficacy, safety and cost of a new second-generation depot antipsychotic medication
L. Citrome
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2010)
Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study
Michelle Kramer et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2010)
Designing outcome studies to determine efficacy and safety of antipsychotics for 'real world' treatment of schizophrenia
A. Carlo Altamura et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2010)
Antipsychotic Polypharmacy and Risk of Death From Natural Causes in Patients With Schizophrenia: A Population-Based Nested Case-Control Study
Lone Baandrup et al.
JOURNAL OF CLINICAL PSYCHIATRY (2010)
Strategies for Improving Treatment Adherence in Schizophrenia and Schizoaffective Disorder
Donald C. Goff et al.
JOURNAL OF CLINICAL PSYCHIATRY (2010)
A Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of 3 Doses of Paliperidone Palmitate in Adults With Acutely Exacerbated Schizophrenia
Gahan J. Pandina et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2010)
Incidence and persistence of tardive dyskinesia and extrapyramidal symptoms in schizophrenia
D. E. Tenback et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2010)
A Controlled, Evidence-Based Trial of Paliperidone Palmitate, A Long-Acting Injectable Antipsychotic, in Schizophrenia
Henry A. Nasrallah et al.
NEUROPSYCHOPHARMACOLOGY (2010)
Relapse Prevention in Schizophrenia and Schizoaffective Disorder with Risperidone Long-Acting Injectable vs Quetiapine: Results of a Long-Term, Open-Label, Randomized Clinical Trial
Wolfgang Gaebel et al.
NEUROPSYCHOPHARMACOLOGY (2010)
Effect of bromocriptine on antipsychotic drug-induced hyperprolactinemia: Eight-week randomized, single-blind, placebo-controlled, multicenter study
Moon-Soo Lee et al.
PSYCHIATRY AND CLINICAL NEUROSCIENCES (2010)
The Schizophrenia Patient Outcomes Research Team (PORT): Updated Treatment Recommendations 2009
Julie Kreyenbuhl et al.
SCHIZOPHRENIA BULLETIN (2010)
The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements
Robert W. Buchanan et al.
SCHIZOPHRENIA BULLETIN (2010)
Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: A double-blind, placebo-controlled trial
Preeta Kaur Narula et al.
SCHIZOPHRENIA RESEARCH (2010)
Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled study
David Hough et al.
SCHIZOPHRENIA RESEARCH (2010)
Maintenance treatment with quetiapine versus discontinuation after one year of treatment in patients with remitted first episode psychosis: randomised controlled trial
Eric Y. H. Chen et al.
BMJ-BRITISH MEDICAL JOURNAL (2010)
A double-blind, placebo-controlled trial of rosiglitazone for clozapine-induced glucose metabolism impairment in patients with Schizophrenia
D. C. Henderson et al.
ACTA PSYCHIATRICA SCANDINAVICA (2009)
How to read and understand and use systematic reviews and meta-analyses
S. Leucht et al.
ACTA PSYCHIATRICA SCANDINAVICA (2009)
Somatic Hospital Contacts, Invasive Cardiac Procedures, and Mortality From Heart Disease in Patients With Severe Mental Disorder
Thomas Munk Laursen et al.
ARCHIVES OF GENERAL PSYCHIATRY (2009)
Antipsychotic long-acting injections: mind the gap
Maxine X. Patel et al.
BRITISH JOURNAL OF PSYCHIATRY (2009)
Harmonizing the Metabolic Syndrome A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity
K. G. M. M. Alberti et al.
CIRCULATION (2009)
Akathisia and second-generation antipsychotic drugs
Rajeev Kumar et al.
CURRENT OPINION IN PSYCHIATRY (2009)
Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: Results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR)
J. M. Olivares et al.
EUROPEAN PSYCHIATRY (2009)
Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC)
M. De Hert et al.
EUROPEAN PSYCHIATRY (2009)
Olanzapine: review of safety
L. Citrome
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2009)
A Randomized Controlled Trial of Long-Acting Injectable Risperidone vs Continuation on Oral Atypical Antipsychotics for First-Episode Schizophrenia Patients: Initial Adherence Outcome
Peter J. Weiden et al.
JOURNAL OF CLINICAL PSYCHIATRY (2009)
Topiramate add-on treatment in schizophrenia: a randomised, double-blind, placebo-controlled clinical trial
H. Afshar et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2009)
Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis
Stefan Leucht et al.
LANCET (2009)
How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials
S. Leucht et al.
MOLECULAR PSYCHIATRY (2009)
Rosiglitazone in the Assistance of Metabolic Control during Olanzapine Administration in Schizophrenia: A Pilot Double-blind, Placebo-controlled, 12-week Trial
T. Baptista et al.
PHARMACOPSYCHIATRY (2009)
Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia
David Hough et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2009)
Does switching to a new antipsychotic improve outcomes? Data from the CATIE Trial
Robert A. Rosenheck et al.
SCHIZOPHRENIA RESEARCH (2009)
Results of phase 3 of the CATIE schizophrenia trial
T. Scott Stroup et al.
SCHIZOPHRENIA RESEARCH (2009)
The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2009 on the Treatment of Acute Mania
Heinz Grunze et al.
WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY (2009)
Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: A double-blind, placebo-controlled study
Ren-Rong Wu et al.
AMERICAN JOURNAL OF PSYCHIATRY (2008)
Role of metformin for weight management in patients without type 2 diabetes
Alicia R. Desilets et al.
ANNALS OF PHARMACOTHERAPY (2008)
Tardive dyskinesia and new antipsychotics
Christoph U. Correll et al.
CURRENT OPINION IN PSYCHIATRY (2008)
Do effectiveness (real world) studies on antipsychotics tell us the real truth?
Hans-Juergen Moeller
EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE (2008)
Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: a study with risperidone long-acting injection
Robin Emsley et al.
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2008)
A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine
John W. Newcomer et al.
JOURNAL OF CLINICAL PSYCHIATRY (2008)
An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia
John Lauriello et al.
JOURNAL OF CLINICAL PSYCHIATRY (2008)
Orlistat in clozapine- or olanzapine-treated patients with overweight or obesity:: A 16-week randomized, double-blind, placebo-controlled trial
Grigori Joffe et al.
JOURNAL OF CLINICAL PSYCHIATRY (2008)
Reduction in neuroleptic-induced movement disorders after a switch to quetiapine in patients with schizophrenia
Leonardo Cortese et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2008)
A randomized, crossover comparison of herbal medicine and bromocriptine against risperidone-induced hyperprolactinemia in patients with schizophrenia
Hai-Ning Yuan et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2008)
Patterns of physician and patient rated quality of life during antipsychotic treatment in outpatients with schizophrenia
Peter M. Wehmeier et al.
JOURNAL OF PSYCHIATRIC RESEARCH (2008)
Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder:: an open randomised clinical trial
Rene S. Kahn et al.
LANCET (2008)
Bilateral Deep Brain Stimulation of the Globus Pallidus Internus in Tardive Dystonia
Wataru Sako et al.
MOVEMENT DISORDERS (2008)
Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole
Mong-Liang Lu et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2008)
Metformin for metabolic dysregulation in schizophrenic patients treated with olanzapine
Chun-Hsin Chen et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2008)
Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia:: A 12-week double-blind, placebo-controlled pilot study
Trino Baptista et al.
PSYCHIATRY RESEARCH (2008)
Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: A retrospective chart review
Marc De Hert et al.
SCHIZOPHRENIA RESEARCH (2008)
How to grade categories of evidence
Borwin Bandelow et al.
WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY (2008)
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders - First Revision
Borwin Bandelow et al.
WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY (2008)
Employment outcomes in a randomized trial of second-generation antipsychotics and perphenazine in the treatment of individuals with schizophrenia
Sandra G. Resnick et al.
JOURNAL OF BEHAVIORAL HEALTH SERVICES & RESEARCH (2008)
Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidone
Peter J. Weiden et al.
NEUROPSYCHOPHARMACOLOGY (2008)
Long-term safety and efficacy of long-acting risperidone in elderly psychotic patients
Werner Kissling et al.
HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL (2007)
A pilot study of a weight management program with food provision in schizophrenia
Michel Jean-Baptiste et al.
SCHIZOPHRENIA RESEARCH (2007)
Maintenance treatment with risperidone or low-dose haloperidol in first-episode schizophrenia:: 1-Year results of a randomized controlled trial within the German research network on schizophrenia
Wolfgang Gaebel et al.
JOURNAL OF CLINICAL PSYCHIATRY (2007)
Adjunctive treatment with a dopamine partial agonist, aripiprazole, for anti psychotic-induced hyperprolactinemia: A placebo-controlled trial
Joo-Cheol Shim et al.
AMERICAN JOURNAL OF PSYCHIATRY (2007)
Seizure incidence in psychopharmacological clinical trials: An analysis of food and drug administration (FDA) summary basis of approval reports
Kenneth Alper et al.
BIOLOGICAL PSYCHIATRY (2007)
Equivalent switching dose from oral risperidone to risperidone long-acting injection: A 48-week randomized, prospective, single-blind pharmacokinetic study
Ya Mei Bai et al.
JOURNAL OF CLINICAL PSYCHIATRY (2007)
Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder - Randomised, controlled, open-label study
Nicholas A. Keks et al.
BRITISH JOURNAL OF PSYCHIATRY (2007)
Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: A randomized, double-blind 52-week comparison
Joseph P. McEvoy et al.
AMERICAN JOURNAL OF PSYCHIATRY (2007)
Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration:: A multicentric, double-blind, placebo-controlled trial
Trino Baptista et al.
SCHIZOPHRENIA RESEARCH (2007)
Guide discontinuaton vesus maintenance treatment in remitted first-episode psychosis: Relapse rates and functional outcome
Lex Wunderink et al.
JOURNAL OF CLINICAL PSYCHIATRY (2007)
Interventions to reduce weight gain in schizophrenia
Guy Faulkner et al.
SCHIZOPHRENIA BULLETIN (2007)
The case for long-acting antipsychotic agents in the post-CATIE era
H. A. Nasrallah
ACTA PSYCHIATRICA SCANDINAVICA (2007)
A double-blind, placebo-controlled trial of sibutramine for clozapine-associated weight gain
D. C. Henderson et al.
ACTA PSYCHIATRICA SCANDINAVICA (2007)
Long-term safety and tolerability of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder
Jean-Pierre Lindenmayer et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2007)
Managing an effective treatment for neuroleptic malignant syndrome
Udo Reulbach et al.
CRITICAL CARE (2007)
Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: Observational versus randomized studies results
Josep Maria Haro et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2007)
Effectiveness of switching antipsychotic medications
Susan M. Essock et al.
AMERICAN JOURNAL OF PSYCHIATRY (2006)
Prediction of remission as a combination of symptomatic and functional remission and adequate subjective well-being in 2960 patients with schizophrenia
Martin Lambert et al.
JOURNAL OF CLINICAL PSYCHIATRY (2006)
Effects of an educational intervention on weight gain in patients treated with antipsychotics
Mauro Mauri et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2006)
Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia - Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1)
Peter B. Jones et al.
ARCHIVES OF GENERAL PSYCHIATRY (2006)
Olanzapine and haloperidol in first episode psychosis: Two-year data
A. I. Green et al.
SCHIZOPHRENIA RESEARCH (2006)
A 1-year double-blind study of 2 doses of long-acting risperidone in stable patients with schizophrenia or schizoaffective disorder
George M. Simpson et al.
JOURNAL OF CLINICAL PSYCHIATRY (2006)
Olanzapine-associated neuroleptic malignant syndrome
Nick B. Norgard et al.
PHARMACOTHERAPY (2006)
The prevalence of the 65-kilodalton isoform of glutamic acid decarboxylase autoantibodies by glucose tolerance status in elderly patients from the cardiovascular health study
Emma Barinas-Mitchell et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
Long-acting injectable risperidone compared with zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity
Gabriel Rubio et al.
CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE (2006)
A double-blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization
Steven G. Potkin et al.
SCHIZOPHRENIA RESEARCH (2006)
A comparative efficacy and safety study of long-acting risperidone injection and risperidone oral tablets among hospitalized patients: 12-week randomized, single-blind study
Y. M. Bai et al.
PHARMACOPSYCHIATRY (2006)
Weight loss in overweight patients maintained on atypical antipsychotic agents
F. Centorrino et al.
INTERNATIONAL JOURNAL OF OBESITY (2006)
Improvement in hyperprolactinemia and reproductive comorbidities in patients with schizophrenia switched from conventional antipsychotics or risperidone to olanzapine
Bruce J. Kinon et al.
PSYCHONEUROENDOCRINOLOGY (2006)
Metformin for prevention of weight gain and insulin resistance with olanzapine:: A double-blind placebo-controlled trial
T Baptista et al.
CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE (2006)
Vitamin B6 versus mianserin and placebo in acute neuroleptic-induced akathisia:: A randomized, double-blind, controlled study
C Miodownik et al.
CLINICAL NEUROPHARMACOLOGY (2006)
A 12-week, randomized, open-label, parallel-group trial of topiramate in limiting weight gain during olanzapine treatment in patients with schizophrenia
JH Kim et al.
SCHIZOPHRENIA RESEARCH (2006)
Tardive dyskinesia: Analysis of outpatients with schizophrenia from Africa and the Middle East, Asia, Central and Eastern Europe, and Latin America
S Kasper et al.
SCHIZOPHRENIA RESEARCH (2006)
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: Long-term treatment of schizophrenia
P Falkai et al.
WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY (2006)
Using aripiprazole to resolve antipsychotic-induced symptomatic hyperprolactinemia: A pilot study
Bun-Hee Lee et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2006)
Quality of life during treatment with haloperidol or olanzapine in the year following a first psychotic episode
SM Strakowski et al.
SCHIZOPHRENIA RESEARCH (2005)
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia
JA Lieberman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Double-blind, placebo-controlled investigation of amantadine for weight loss in subjects who gained weight with olanzapine
KA Graham et al.
AMERICAN JOURNAL OF PSYCHIATRY (2005)
Effects of antipsychotic treatment on tardive dyskinesia: A 6-month evaluation of patients from the European Schizophrenia Outpatient Health Outcomes (SOHO) study
DE Tenback et al.
JOURNAL OF CLINICAL PSYCHIATRY (2005)
Topiramate add-on in treatment-resistant schizophrenia:: A randomized, double-blind, placebo-controlled, crossover trial
J Tiihonen et al.
JOURNAL OF CLINICAL PSYCHIATRY (2005)
Topiramate as an adjuvant treatment with atypical antipsychotics in schizophrenic patients experiencing weight gain
YH Ko et al.
CLINICAL NEUROPHARMACOLOGY (2005)
Lack of impact of race on the efficacy and safety of long-acting risperidone versus placebo in patients with schizophrenia or schizoaffective disorder
N Ciliberto et al.
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2005)
Risperidone and haloperidol in first-episode psychosis: A long-term randomized trial
N Schooler et al.
AMERICAN JOURNAL OF PSYCHIATRY (2005)
Double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain
DC Henderson et al.
AMERICAN JOURNAL OF PSYCHIATRY (2005)
Maintenance treatment of severe tardive dyskinesia with clozapine - 5 years' follow-up
MR Louza et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2005)
Risperidone for pre-existing severe tardive dyskinesia: a 48-week prospective follow-up study
YM Bai et al.
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2005)
Olanzapine-induced hyperprolactinemia and galactorrhea reversed with addition of bromocriptine: A case report
DE Miller et al.
JOURNAL OF CLINICAL PSYCHIATRY (2005)
World Federation of Societies of Biological Psychiatry (WFSBP) - Guidelines for biological treatment of schizophrenia, part 1: Acute treatment of schizophrenia
P Falkai et al.
WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY (2005)
Treatment of severe tardive dystonia with pallidal deep brain stimulation
T Trottenberg et al.
NEUROLOGY (2005)
Long-acting risperidone vs. placebo in the treatment of hospital inpatients with schizophrenia
J Lauriello et al.
SCHIZOPHRENIA RESEARCH (2005)
Amantadine for weight gain associated with olanzapine treatment
W Deberdt et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2005)
Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets
P Chue et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2005)
Drug therapy: Drug-induced prolongation of the QT interval
DM Roden
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Olanzapine treatment for tardive dyskinesia in schizophrenia patients: a prospective clinical trial with patients randomized to blinded dose reduction periods
BJ Kinon et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2004)
Weight decline in patients switching from olanzapine to quetiapine
S Gupta et al.
SCHIZOPHRENIA RESEARCH (2004)
Partial compliance and risk of rehospitalization among California medicaid patients with schizophrenia
PJ Weiden et al.
PSYCHIATRIC SERVICES (2004)
Physical health monitoring of patients with schizophrenia
SR Marder et al.
AMERICAN JOURNAL OF PSYCHIATRY (2004)
Usefulness of bromocriptine in the treatment of amisulpride-induced hyperprolactinemia -: A case report
N Bliesener et al.
PHARMACOPSYCHIATRY (2004)
Vitamin B6 treatment in acute neuroleptic-induced akathisia:: A randomized, double-blind, placebo-controlled study
V Lerner et al.
JOURNAL OF CLINICAL PSYCHIATRY (2004)
Novel antipsychotics in the long-term treatment of schizophrenia
HJ Moller
WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY (2004)
Nizatidine for the treatment of patients with quetiapine-induced weight gain
M Atmaca et al.
HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL (2004)
Impact of atypical antipsychotics on quality of life in patients with schizophrenia
AG Awad et al.
CNS DRUGS (2004)
Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia
S Kasper et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2003)
Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia - A randomized controlled trial
R Rosenheck et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2003)
Risperidone for severe tardive dyskinesia: A 12-week randomized, double-blind, placebo-controlled study
YM Bai et al.
JOURNAL OF CLINICAL PSYCHIATRY (2003)
Behavioural management of antipsychotic-induced weight gain: a review
U Werneke et al.
ACTA PSYCHIATRICA SCANDINAVICA (2003)
Maintenance treatment of schizophrenia with risperidone or haloperidol: 2-year outcomes
SR Marder et al.
AMERICAN JOURNAL OF PSYCHIATRY (2003)
Nizatidine treatment and its relationship with leptin levels in patients with olanzapine-induced weight gain
M Atmaca et al.
HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL (2003)
Relapse prevention in schizophrenia with new-generation antipsychotics: A systematic review and exploratory meta-analysis of randomized, controlled trials
S Leucht et al.
AMERICAN JOURNAL OF PSYCHIATRY (2003)
Long-acting injectable risperidone: Efficacy and safety of the first long-acting atypical antipsychotic
JM Kane et al.
AMERICAN JOURNAL OF PSYCHIATRY (2003)
A meta-analysis of the efficacy of second-generation antipsychotics
JM Davis et al.
ARCHIVES OF GENERAL PSYCHIATRY (2003)
Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia
PJ Weiden et al.
JOURNAL OF CLINICAL PSYCHIATRY (2003)
Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study
DE Casey et al.
PSYCHOPHARMACOLOGY (2003)
Nizatidine for prevention of weight gain with olanzapine: a double-blind placebo-controlled trial
P Cavazzoni et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2003)
Treatment of weight gain with fluoxetine in olanzapine-treated schizophrenic outpatients
JR Bustillo et al.
NEUROPSYCHOPHARMACOLOGY (2003)
The effects of an educational intervention on antipsychotic-induced weight gain
KH Littrell et al.
JOURNAL OF NURSING SCHOLARSHIP (2003)
Clozapine treatment for suicidality in schizophrenia - International Suicide Prevention Trial (InterSePT)
HY Meltzer et al.
ARCHIVES OF GENERAL PSYCHIATRY (2003)
Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone
PJ Weiden et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2003)
Pharmacological management of first-episode schizophrenia and related nonaffective psychoses
DW Bradford et al.
DRUGS (2003)
The effects of novel antipsychotics on glucose and lipid levels
DA Wirshing et al.
JOURNAL OF CLINICAL PSYCHIATRY (2002)
Olanzapine-induced weight gain in patients with first-episode schizophrenia: A double-blind, placebo-controlled study of fluoxetine addition
M Poyurovsky et al.
AMERICAN JOURNAL OF PSYCHIATRY (2002)
Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone
KS Kim et al.
JOURNAL OF CLINICAL PSYCHIATRY (2002)
A multidose study of haloperidol decanoate in the maintenance treatment of schizophrenia
JM Kane et al.
AMERICAN JOURNAL OF PSYCHIATRY (2002)
A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia
JG Csernansky et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Social functioning and quality of life in the schizophrenic patient: advantages of amisulpride
P Saleem et al.
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2002)
First vs multiple episode schizophrenia: two-year outcome of intermittent and maintenance medication strategies
W Gaebel et al.
SCHIZOPHRENIA RESEARCH (2002)
Antipsychotic drugs: Prolonged QTc interval, torsade de pointes, and sudden death
AH Glassman et al.
AMERICAN JOURNAL OF PSYCHIATRY (2001)
Systematic review of patient and nurse attitudes to depot antipsychotic medication
J Walburn et al.
BRITISH JOURNAL OF PSYCHIATRY (2001)
Systematic meta-review of depot antipsychotic drugs for people with schizophrenia
CE Adams et al.
BRITISH JOURNAL OF PSYCHIATRY (2001)
Metformin in obesity associated with antipsychotic drug administration:: A pilot study
T Baptista et al.
JOURNAL OF CLINICAL PSYCHIATRY (2001)
Cognitive behavior therapy for weight gain
D Umbricht et al.
AMERICAN JOURNAL OF PSYCHIATRY (2001)
Rapid onset of therapeutic effect of risperidone versus haloperidol in a double-blind randomized trial
J Rabinowitz et al.
JOURNAL OF CLINICAL PSYCHIATRY (2001)
Effect of amantadine on weight gain during olanzapine treatment
M Floris et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2001)
Diphenhydramine for the prevention of akathisia induced by prochlorperazine: A randomized, controlled trial
DR Vinson et al.
ANNALS OF EMERGENCY MEDICINE (2001)
Orlistat in the treatment of psychopharmacologically induced weight gain
I Anghelescu et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2000)
Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia:: results of a multicentre, double-blind study (the Amisulpride Study Group)
P Carrière et al.
EUROPEAN PSYCHIATRY (2000)
H2 antagonist nizatidine may control olanzapine-associated weight gain in schizophrenic patients
E Sacchetti et al.
BIOLOGICAL PSYCHIATRY (2000)
Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life
L Voruganti et al.
SCHIZOPHRENIA RESEARCH (2000)
Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia
L Colonna et al.
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2000)
Functional outcomes in schizophrenia: a comparison of olanzapine and haloperidol in a European sample
SH Hamilton et al.
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2000)
分享论文
